Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: A retrospective study

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1363-1371

  Beltrame, L ^a   Di Marino, M ^a   Fruscio, R ^a,b   Calura, E ^c   Chapman, B ^d   Clivio, L ^a   Sina, F ^b   Mele, C ^a   Iatropoulos, P ^a   Grassi, T ^b   Fotia, V ^e   Romualdi, C ^c   Martini, P ^c   Noris, M ^a   Paracchini, L ^a   Craparotta, I ^a   Petrillo, M ^f   Milani, R ^b   Perego, P ^b   Ravaggi, A ^g   Zambelli, A ^h   Ronchetti, E ⁱ   D'Incalci, Maurizio ^a   Marchini, S ^a   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

ⁱ IRCCS   (Italy)

Author keywords

Epithelial ovarian cancer; Matched tumor biopsies; NGS

Indexed keywords

ATM PROTEIN; ATR PROTEIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ATM GENE; ATR GENE; BIOGENESIS; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN TISSUE; INDEL MUTATION; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OVARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TOP2A GENE; TOP2B GENE; TUMOR BIOPSY; TUMOR GENE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; BIOPSY; CANCER GRADING; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE; ENDOMETRIAL NEOPLASMS; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; LONGITUDINAL STUDY; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENES, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HOMOLOGOUS RECOMBINATION; HUMANS; LONGITUDINAL STUDIES; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84946714282     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv164     Document Type: Article

References (18)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
2. Bast RC, Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415-428.
3. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-250.
4. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-861.
5. Stockler MR, Hilpert F, Friedlander M et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 2014; 32: 1309-1316.
6. Network TCGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
7. Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010; 12: R75.
8. Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101: 9393-9398.
9. Mittendorf EA, Wu Y, Scaltriti M et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15: 7381-7388.
10. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Messier W, Stewart CB. Episodic adaptive evolution of primate lysozymes. Nature 1997; 385: 151-154.
13. Pennington KW, Harrell M, Lee M et al. Deep sequencing reveals a high rate of temporal heterogeneity of somatic mutations in paired primary and recurrent ovarian carcinomas. Gynecol Oncol 2013; 131: 248-276.
14. Pennington KP, Walsh T, Harrell MI et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20:764-775.
15. Castellarin M, Milne K, Zeng T et al. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol 2013; 229: 515-524.
16. Bashashati A, Ha G, Tone A et al. Distinct evolutionary trajectories of primary highgrade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013; 231: 21-34.
17. Teng P, Bateman NW, Darcy KM et al. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol Oncol 2015; 136:554-561.
18. Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet 2014; 30:326-339.